Radiopharmaceuticals in Nuclear Medicine Market by Product Type (Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals, and PET Radiopharmaceuticals) and Therapeutic Nuclear Medicine), By Application (Oncology, Cardiology, Neurology, Endocrinology, and Others), By End User (Hospitals, Specialty Clinics, and Diagnostic Centers) and By Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

  • Published On : May 2019 |
  • Pages : 279 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Radiopharmaceuticals in Nuclear Medicine Market – Insights

Radiopharmaceuticals are medicinal formulations that contain radioisotopes, which are used in major clinical areas for diagnosis and/or therapy. Radiopharmaceuticals have several applications in diagnostic as well as therapeutic areas in nuclear medicine. There are around 50 U.S. Food & Drug Administration (FDA) approved radiopharmaceuticals present in the market for diagnostic and therapeutic applications. Technetium -99m has vast number of applications in diagnostic imaging using radiopharmaceuticals. Areas where radiopharmaceuticals have applications include oncology, neurology, hematology, cardiology, thyroid applications, and others. Moreover, certain radiopharmaceuticals have diagnostic as well as therapeutic applications such as certain iodine isotopes.

Vast number of applications of radiopharmaceuticals is expected to boost global radiopharmaceuticals in nuclear medicine market growth over the forecast period

Oncology applications include cancer diagnosis and treatment effectiveness determination (using radiolabeled therapeutics). Moreover, basic cancer physiology detection is also possible with the help of radiopharmaceuticals. For instance, Fluorine-18 fludeoxyglucose is indicated for assessing abnormal glucose metabolism in tumors. Neurology applications include evaluation of Alzheimer's disease and epileptic seizures. Radiopharmaceuticals such as Vizamyl (GE Healthcare), Amyvid (Eily, Lilly, and Company), and Neuraceq (Life Molecular Imaging) are indicated to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment, who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline. Hematology applications include determination of total blood volume, plasma volume, cardiac output, glomerular filtration, and other tests. Products used in hematology include Jeanatope, Megatope, and Glofil-125 manufactured by IsoTex Diagnostics. Cardiology applications mainly include myocardial perfusion imaging for distinguishing normal from abnormal myocardium in patients with suspected myocardial infarction and other applications.

The global radiopharmaceuticals in nuclear medicine market size was valued at US$ 4,986.4 million in 2017 and is expected to witness a robust CAGR of 8.9% over the forecast period (2018–2026).

Figure 1. Global Radiopharmaceuticals in Nuclear Medicine Market Share (%), by Region

    Radio Pharmaceuticals  | Coherent Market Insights 

   Source: Coherent Market Insights Analysis (2017)

Use of hybrid imaging in diagnosis is expected to boost growth of the global radiopharmaceuticals in nuclear medicine market over the forecast period

 

Technological advancements in imaging have brought many changes such as the introduction of hybrid technology — positron emission tomography/computed tomography (PET/CT) and single-photon emission computed tomography/computed tomography (SPECT/CT). Combination of the anatomic details provided, for instance, by CT, with the important and much needed functional, physiologic or metabolic information provided by molecular imaging has been facilitated with the use of hybrid imaging. More accurate diagnosis is possible with the help of hybrid imaging with increased specificity, attenuation correction, and localization. Moreover, usage of PET/CT has been established in clinical practice and has added significant value in the areas of neurology, cardiology, and oncology. Moreover, SPECT/CT has also been established and has been used in areas such as cardiology, liver/spleen imaging, thyroid imaging, cancer diagnosis, and others. Hybrid imaging (PET/CT) along with radiopharmaceuticals such as 18F-fluorodeoxyglucose (18F-FDG), the most frequently used molecule in the PET diagnosis, 18F-fluorothymidine (18F-FLT), 18F-fluorocholine (18F-FCH), 18F-fluoro-ethyltyrosine (18F-FET), 18F-fluorodihydroxyphenylalanine (18F-FDOPA), 11C-methionine (11C-MET) or 18F-fluoromisonidazole (18F-FMISO), 68Ga-DOTA derivatives, 68Ga-PSMA, 18F-florbetaben or 18F-flutemetamol for brain amyloid beta imaging has been widely used (according to European Journal of Radiology, 2017). These factors drive growth of the market and further developments in PET cameras and other technologies is expected to boost growth of the market over the forecast period.

Figure 2. Global Radiopharmaceuticals in Nuclear Medicine Market Share (%) by Product Type

        Radio Pharmaceuticals  | Coherent Market Insights

However, factors such as high costs of development of radiopharmaceuticals relative to return on investment, supply shortage of radiopharmaceuticals, and short half-life of radiopharmaceuticals is expected to restrain growth of the radiopharmaceuticals in nuclear medicine market over the forecast period.

Some major players operating in the global radiopharmaceuticals in nuclear medicine market include Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Pharma, Life Molecular Imaging, Lantheus Holdings, Inc., Cardinal Health, Inc., General Electric Company, Bracco S.p.A., Bayer AG, Advanced Accelerator Applications, S.A., and Eli Lilly and Company.

Licensing, regulations, and use of radioisotopes in the U.S. is under agencies such as the U.S. Nuclear Regulatory Commission (NRC), the U.S. Environmental Protection Agency (EPA), the U.S. Food & Drug Administration (FDA), and respective state governments. The state governments are responsible for regulating radioactive substances that occur naturally or are produced by linear accelerators and/or cyclotrons, and EPA is responsible for among other things, setting air emission and drinking water standards for radionuclides. The U.S. Food and Drug Administration (FDA) regulates manufacturing and use of linear accelerators; granting marketing authorizations to radiopharmaceutical products for diagnostic as well as therapeutic use and other activities associated with radiopharmaceutical products.

Market Dynamics

Factors such as approval of products such as Lutathera, a potential blockbuster drug (Advanced Accelerator Applications, 2018) and Axumin (2016, Blue Earth Diagnostics) has propelled global radiopharmaceuticals in nuclear medicine market growth. Newer trends such as increasing therapeutic applications of radiopharmaceuticals and radiolabeling of monoclonal antibodies are expected to support growth of the market. Subsequently, as the need for early diagnosis of diseases such as cancer and accurate diagnosis of diseases such as Alzheimer's has become more necessary (certain products have come close to this such as Amyvid and Vizamyl) radiopharmaceuticals are expected to find an even strong foothold in medical care.

Key features of the study:

  • This report provides in-depth analysis of global radiopharmaceuticals in nuclear medicine market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018–2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global radiopharmaceuticals in nuclear medicine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key companies covered as a part of this study include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global radiopharmaceuticals in nuclear medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global radiopharmaceuticals in nuclear medicine market

Detailed Segmentation:

  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type:
    • Diagnostic Nuclear Medicine
      • SPECT Radiopharmaceuticals                
        • Tc-99m
        • In-111
        • Tl-201
        • Ga-67
        • I-123/I-125/I-131
        • Other SPECT Isotopes
      • PET Radiopharmaceuticals
        • F-18
          • F-18 Florbetapir/Flutemetamol/ Florbetaben
          • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
          • Fluorine-18 Fluciclovine
          • Other F-18 Isotopes
        • Ru-82
        • Other PET Isotopes
    • Therapeutic Nuclear Medicine
      • Ra-223
      • I-131
      • Re-186/Sm-153/Sr-90
      • Lu-177
      • Ir-192
      • Pd-103
      • Cs-131
      • Others
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Region:
    • North America
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals                
            • Tc-99m
            • In-111
            • Tl-201
            • Ga-67
            • I-123/I-125/I-131
            • Other SPECT Isotopes
          • PET Radiopharmaceuticals
            • F-18
              • F-18 Florbetapir/Flutemetamol/ Florbetaben
              • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
              • Fluorine-18 Fluciclovine
              • Other F-18 Isotopes
            • Ru-82
            • Other PET Isotopes
        • Therapeutic Nuclear Medicine
          • Ra-223
          • I-131
          • Re-186/Sm-153/Sr-90
          • Lu-177
          • Ir-192
          • Pd-103
          • Cs-131
          • Others
      • By Application:
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers
      • By Country:
        • U.S.
        • Canada
    • Europe
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals                
            • Tc-99m
            • In-111
            • Tl-201
            • Ga-67
            • I-123/I-125/I-131
            • Other SPECT Isotopes
          • PET Radiopharmaceuticals
            • F-18
              • F-18 Florbetapir/Flutemetamol/ Florbetaben
              • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
              • Fluorine-18 Fluciclovine
              • Other F-18 Isotopes
            • Ru-82
            • Other PET Isotopes
        • Therapeutic Nuclear Medicine
          • Ra-223
          • I-131
          • Re-186/Sm-153/Sr-90
          • Lu-177
          • Ir-192
          • Pd-103
          • Cs-131
          • Others
      • By Application:
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals                
            • Tc-99m
            • In-111
            • Tl-201
            • Ga-67
            • I-123/I-125/I-131
            • Other SPECT Isotopes
          • PET Radiopharmaceuticals
            • F-18
              • F-18 Florbetapir/Flutemetamol/ Florbetaben
              • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
              • Fluorine-18 Fluciclovine
              • Other F-18 Isotopes
            • Ru-82
            • Other PET Isotopes
        • Therapeutic Nuclear Medicine
          • Ra-223
          • I-131
          • Re-186/Sm-153/Sr-90
          • Lu-177
          • Ir-192
          • Pd-103
          • Cs-131
          • Others
      • By Application:
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers 
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals                
            • Tc-99m
            • In-111
            • Tl-201
            • Ga-67
            • I-123/I-125/I-131
            • Other SPECT Isotopes
          • PET Radiopharmaceuticals
            • F-18
              • F-18 Florbetapir/Flutemetamol/ Florbetaben
              • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
              • Fluorine-18 Fluciclovine
              • Other F-18 Isotopes
            • Ru-82
            • Other PET Isotopes
        • Therapeutic Nuclear Medicine
          • Ra-223
          • I-131
          • Re-186/Sm-153/Sr-90
          • Lu-177
          • Ir-192
          • Pd-103
          • Cs-131
          • Others
      • By Application:
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers 
      • By Country:
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals                
            • Tc-99m
            • In-111
            • Tl-201
            • Ga-67
            • I-123/I-125/I-131
            • Other SPECT Isotopes
          • PET Radiopharmaceuticals
            • F-18
              • F-18 Florbetapir/Flutemetamol/ Florbetaben
              • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
              • Fluorine-18 Fluciclovine
              • Other F-18 Isotopes
            • Ru-82
            • Other PET Isotopes
        • Therapeutic Nuclear Medicine
          • Ra-223
          • I-131
          • Re-186/Sm-153/Sr-90
          • Lu-177
          • Ir-192
          • Pd-103
          • Cs-131
          • Others
      • By Application:
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers 
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
        • Diagnostic Nuclear Medicine
          • SPECT Radiopharmaceuticals                
            • Tc-99m
            • In-111
            • Tl-201
            • Ga-67
            • I-123/I-125/I-131
            • Other SPECT Isotopes
          • PET Radiopharmaceuticals
            • F-18
              • F-18 Florbetapir/Flutemetamol/ Florbetaben
              • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
              • Fluorine-18 Fluciclovine
              • Other F-18 Isotopes
            • Ru-82
            • Other PET Isotopes
        • Therapeutic Nuclear Medicine
          • Ra-223
          • I-131
          • Re-186/Sm-153/Sr-90
          • Lu-177
          • Ir-192
          • Pd-103
          • Cs-131
          • Others
      • By Application:
        • Oncology
        • Cardiology
        • Neurology
        • Endocrinology
        • Others
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Diagnostic Centers 
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Progenics Pharmaceuticals, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • NorthStar Medical Radioisotopes LLC
    • Curium Pharma
    • Life Molecular Imaging
    • Lantheus Holdings, Inc.
    • Cardinal Health, Inc.
    • General Electric Company
    • Bracco S.p.A.
    • Bayer AG
    • Advanced Accelerator Applications, S.A.
    • Eli Lilly and Company

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Application
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Regulatory Scenario
    • Reimbursement Scenario
    • PEST Analysis
    • Porter’s Analysis
    • Collaborations & Partnerships
    • Mergers & Acquisitions
    • Key Developments
    • Epidemiology
  4. Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018–2026
      • Segment Trends
    • Diagnostic Nuclear Medicine
      • SPECT Radiopharmaceuticals           
        • Tc-99m
        • In-111
        • Tl-201
        • Ga-67
        • I-123/I-125/I-131
        • Other SPECT Isotopes
      • PET Radiopharmaceuticals
        • F-18
          • F-18 Florbetapir/Flutemetamol/ Florbetaben
          • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
          • Fluorine-18 Fluciclovine
          • Other F-18 Isotopes
        • Ru-82
        • Other PET Isotopes
    • Therapeutic Nuclear Medicine
      • Ra-223
      • I-131
      • Re-186/Sm-153/Sr-90
      • Lu-177
      • Ir-192
      • Pd-103
      • Cs-131
      • Others
  5. Global Radiopharmaceuticals in Nuclear Medicine Market, By Application, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018–2026
      • Segment Trends
    • Oncology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Cardiology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Neurology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Endocrinology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  6. Global Radiopharmaceuticals in Nuclear Medicine Market, By End User, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018–2026
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Specialty Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Diagnostic Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  7. Global Radiopharmaceuticals in Nuclear Medicine Market, By Regions, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2026
    • North America
      • Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • Brazil
        • Mexico
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Progenics Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • NorthStar Medical Radioisotopes LLC
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Curium Pharma
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Life Molecular Imaging
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Lantheus Holdings, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Cardinal Health, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • General Electric Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bracco S.p.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Advanced Accelerator Applications, S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 50 market data tables and 53 figures on "Radiopharmaceuticals in Nuclear Medicine Market - Global forecast to 2026”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.